Phare Bio Analysis: $27M Raised
What is Phare Bio?
Generative AI platform for antibiotic discovery
Location
Boston, United States
Employees
11-50
Founded
2020
Product Features & Capabilities
- AIBiotics generative AI antibiotics discovery engine
- Hit-to-Lead Optimization
- Preclinical Development
- Clinical Development
Use Cases
Design novel antibiotics against Acinetobacter baumannii; Develop antibiotics for Pseudomonas aeruginosa; Conduct drug metabolism and toxicology assays; Test drug delivery in preclinical studies; Partner with pharma for clinical trials
Other Considerations
Selected for Google.org's Generative AI Accelerator; Backed by TED's Audacious Project; Received $27 million from ARPA-H; Named to Fast Company’s 2025 World Changing Ideas list; Winner of Newsweek’s AI Impact Award
See something that needs updating? Suggest edits to this profile.